Exact Sciences logo

EXAS - Exact Sciences News Story

$120.51 -7.0  -5.5%

Last Trade - 29/10/20

Sector
Healthcare
Size
Large Cap
Market Cap £15.62bn
Enterprise Value £15.85bn
Revenue £1.02bn
Position in Universe 446th / 6403

BUZZ-Cowen sees huge market opportunity for liquid biopsy

Fri 18th September, 2020 11:26am
** Cowen and Co detects a huge market opportunity for liquid
biopsies and believes revenue will grow at robust double-digit
rates through most of next decade
    ** Liquid biopsies are non-invasive diagnostics tests that
are used for cancer detection
    ** Brokerage estimates market opportunity across all classes
of liquid biopsies is at least $30 bln-$130 bln in U.S.
    ** Key players include Adaptive Biotechnologies Corp
 ADPT.O , Exact Sciences Corp  EXAS.O , Gaurdant Health Inc
 GH.O , Natera Inc  NTRA.O , Invitae Corp  NVTA.N , Illumina Inc
 ILMN.O , and Personalis Inc  PSNL.O 
    ** Despite 100+ companies now developing or commercializing
liquid biopsy products as well as regulatory progress, the
market opportunity remains large, promising, and
under-penetrated - Cowen

 (Reporting By Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.